Clinical Edge Journal Scan

Family history of breast cancer increases likelihood of dense breast in premenopausal women


 

Key clinical point: A family history of breast cancer (FHBC) was positively associated with mammographic breast density in premenopausal women, highlighting the role of heredity and the need for initiating early annual screening in women with an FHBC.

Major finding: The volumetric percent density was 25% higher among premenopausal women with vs. without FHBC (odds ratio [OR] 1.25; 95% CI 1.12-1.41) in the discovery cohort, and the odds of having a dense breast was 30% higher in premenopausal women with vs. without FHBC in the validation cohort (OR 1.30; 95% CI 1.17-1.45).

Study details: This study evaluated two retrospective cohorts, a discovery set of 375 premenopausal women and a validation set of 14,040 premenopausal women without any history of cancer, including breast cancer, or breast augmentation/reduction.

Disclosures: This study was supported by US National Institutes of Health (NIH)/National Cancer Institute and the National Institute on Minority Health and Health Disparities of the NIH. The authors declared no conflicts of interest.

Source: Han Y et al. Family history of breast cancer and mammographic breast density in premenopausal women. JAMA Netw Open. 2022;5(2):e2148983 (Feb 17). Doi: 10.1001/jamanetworkopen.2021.48983

Recommended Reading

Aspirin fails to inhibit breast cancer recurrence
MDedge Hematology and Oncology
15th Report on Carcinogens Adds to Its List
MDedge Hematology and Oncology
MRI with mammogram reduces breast cancer mortality by more than 50% in high-risk women
MDedge Hematology and Oncology
Heavy drinking in your 20s has lasting impact on cancer risk
MDedge Hematology and Oncology
FDA approves first PARP inhibitor for early BRCA+ breast cancer
MDedge Hematology and Oncology
TNBC: Neoadjuvant and adjuvant pembrolizumab prolongs EFS in KEYNOTE-522
MDedge Hematology and Oncology
Atezolizumab fails to improve pCR in early TNBC
MDedge Hematology and Oncology
Lobular vs. ductal histology worsens outcomes in metastatic breast cancer
MDedge Hematology and Oncology
HD201 equivalent to referent trastuzumab in ERBB2-positive early BC
MDedge Hematology and Oncology
Metastatic BC: Adding pertuzumab to trastuzumab+chemotherapy prolongs survival in the real world
MDedge Hematology and Oncology